Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor ablation cases in Michigan: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (83 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 270 | 45% |
| 2020 | 0 | 223 | 51% |
| 2021 | 0 | 250 | 55% |
| 2022 | 0 | 255 | 59% |
| 2023 | 1 | 243 | 63% |
| 2024 | 0 | 228 | 66% |
| 2025 from claims | – | 302 245–355 | 67% |
| 2026 forecast | – | 318 249–399 | 67% |
| 2027 forecast | – | 331 245–437 | 68% |
| 2028 forecast | – | 344 243–474 | 69% |
| 2029 forecast | – | 357 243–512 | 70% |
| 2030 forecast | – | 370 243–550 | 70% |
Percutaneous liver, kidney, lung, and bone tumor ablation. Professional codes (what the surgeon bills): CPT 47382, 47383, 50592, 50593, 32998, 20982, 20983.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
No metro breakdown yet.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Minnesota | 7 | 358+1.3%/yr | +1.3%/yr | 0.8 | 0% | 500 in 2030+5.8%/yr |
| Illinois | 2 | 357+0.9%/yr | +0.9%/yr | 0.3 | 0% | 740 in 2030+13%/yr |
| Ohio | 1 | 253−4.9%/yr | −4.9%/yr | 0.2 | 0% | 520 in 2030+13%/yr |
| Missouri | 1 | 251−2.1%/yr | −2.1%/yr | 0.4 | 0% | 510 in 2030+12%/yr |
| Wisconsin | 3 | 239−0.5%/yr | −0.5%/yr | 0.4 | 0% | 180 in 2030−5%/yr |
| Indiana | 0 | 141+2.6%/yr | +2.6%/yr | 0.2 | 0% | 190 in 2030+5.5%/yr |
| Kansas | 2 | 1340%/yr | 0%/yr | 0.3 | 0% | 320 in 2030+15%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 102 | 5,736−6.4%/yr | −6.4%/yr | 7.31.0× | 5% | 5,320 in 2030−1.2%/yr |
| Tumor & fibroid embolization | 7 | 565+12%/yr | +12%/yr | 0.71.4× | 78% | 1,300 in 2030+15%/yr |
Tumor ablation in every state, and its device makers · Every procedure market in Michigan · Every state · Compare with Minnesota
Exact Sciences leads with 53% of company spending on these surgeons in 2025, +2 pts on 2024.
In 2025, 17 companies reported engagement with Michigan’s surgeons worth $250K in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 5 recalled product lines (3 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.